Optical Coherence Tomography Market Size, Share, Growth, Trends, and Global Industry Analysis: By Product Type (Portable/Handheld, Table Top) By Application (Ophthalmic Diagnosis, Dermatology) By Technology (Spectral Domain OCT, Swept Source OCT) By End-User (Hospitals, Clinics, Others)  and Region Forecast 2021-2032  

Optical Coherence Tomography (OCT) Market size was valued at US$ 3.5 billion in 2025 and is expected to reach US$ 19.8 billion by 2032, growing at a significant CAGR of 28.3% from 2026-2032. The market refers to the global market for advanced, non-invasive imaging systems that use light waves to produce high-resolution, cross-sectional images of biological tissues. OCT technology is widely used in ophthalmology to diagnose and monitor eye conditions such as glaucoma, age-related macular degeneration, and diabetic retinopathy. It is also used in cardiology, dermatology, and other medical specialties for tissue imaging and disease assessment.

The market includes OCT imaging devices, scanners, software, and associated accessories used in hospitals, ophthalmology clinics, diagnostic centers, and research institutions. Market growth is driven by the increasing prevalence of eye disorders, the growing geriatric population, rising demand for early disease diagnosis, and technological advancements in imaging resolution, speed, and artificial intelligence integration. The expansion of applications beyond ophthalmology and the increasing adoption of advanced diagnostic technologies are also creating new opportunities for market participants.

The expanding use of OCT in cardiology, dermatology, oncology, and other medical specialties is further broadening its potential applications. Increasing investments in ophthalmic diagnostic equipment, the expansion of specialized eye-care centers, and the growing demand for advanced medical imaging are expected to create opportunities for OCT device manufacturers and healthcare technology providers.

However, high equipment costs, budget constraints in smaller healthcare facilities, and the need for trained professionals may limit adoption in some markets. Manufacturers focusing on affordable systems, portable devices, AI-enabled analysis, and improved clinical integration may gain a competitive advantage.

Key Developments:

• April 28, 2026: Abbott received U.S. Food and Drug Administration (FDA) clearance and CE Mark for its next-generation Ultreon™ 3.0 AI-powered coronary imaging platform. The system combines high-resolution optical coherence tomography (OCT) imaging with automated artificial intelligence insights to help physicians assess coronary artery blockages, plan stent placement, and evaluate treatment results. This development highlights the growing integration of AI and intravascular OCT in cardiovascular interventions.
• March 3, 2026: Perimeter Medical Imaging AI received FDA approval for its Claire™ OCT System, an AI-enabled imaging platform designed to provide real-time, three-dimensional visualization of excised breast tissue and help identify areas suspicious for cancer at surgical margins. The system combines OCT imaging with computer-aided detection to support physicians during breast-conserving surgery, demonstrating the expanding application of OCT technology beyond ophthalmology.